McKesson
MCK
Market cap $82.5B

663.17 USD

+4.16

0.63%

At close Aug 13, 4:00 PM EDT

After hours

663.17

+0.00

0.00%

1 day

0.63%

5 days

-2.97%

1 month

-7.32%

3 months

-3.58%

6 months

10.08%

Year to date

17.12%

1 year

20.19%

5 years

335.75%

10 years

209.47%

About: McKesson Corp is one of three leading pharmaceutical wholesalers in the US engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the US pharmaceutical wholesale industry. Outside the US market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.

Employees: 51,000

Healthcare Medical Distribution

0

Funds holding %

of 7,338 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 220 | Existing positions closed: 110

44% more funds holding in top 10

Funds holding in top 10: 36 [Q4 2024] → 52 (+16) [Q1 2025]

14% more capital invested

Capital invested by funds: $63.4B [Q4 2024] → $72.6B (+$9.16B) [Q1 2025]

5% more funds holding

Funds holding: 1,644 [Q4 2024] → 1,720 (+76) [Q1 2025]

0.24% more ownership

Funds ownership: 85.84% [Q4 2024] → 86.09% (+0.24%) [Q1 2025]

4% less repeat investments, than reductions

Existing positions increased: 593 | Existing positions reduced: 619

5% less call options, than puts

Call options by funds: $616M | Put options by funds: $648M

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$772

16%

upside

Avg. target

$794

20%

upside

High target

$810

22%

upside

3 analyst ratings

2 positive

67%

1 neutral

33%

0 negative

0%

Wells Fargo Stephen Baxter	16%upside $772	Equal-Weight Maintained	13 Aug 2025
Morgan Stanley Erin Wright	22%upside $810	Overweight Maintained	16 Jul 2025
Evercore ISI Group Elizabeth Anderson	21%upside $800	Outperform Maintained	9 Jul 2025

See Analyst Rankings

Financial journalist opinion

Based on 26 articles about MCK published over the past 30 days

Zacks Investment Research

McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to McKesson (MCK). This makes it worthwhile to examine what the stock has in store.

McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know

Zacks Investment Research

4 Dental Supplies Stocks Likely to Gain Amid Rising Tariff Risks

Here, we discuss four stocks from the Dental Supplies industry that are likely to generate wealth for investors amid tariff uncertainty. These are MCK, CAH, WST and COO.

4 Dental Supplies Stocks Likely to Gain Amid Rising Tariff Risks

Zacks Investment Research

Here's Why McKesson (MCK) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why McKesson (MCK) is a Strong Value Stock

Zacks Investment Research

Dividend Watch: 3 Companies Boosting Payouts

Everybody loves dividends, as they provide a passive income stream, limit drawdowns in other positions, and provide more than one way to profit from an investment.

Dividend Watch: 3 Companies Boosting Payouts

Zacks Investment Research

MCK Stock Down Despite Q1 Earnings Beat & Raised '26 EPS View

McKesson beats on Q1 earnings and raises FY26 EPS view, but shares slip as gross margin narrows and spin-off plans weigh on investors' sentiment.

MCK Stock Down Despite Q1 Earnings Beat & Raised '26 EPS View

Zacks Investment Research

Compared to Estimates, McKesson (MCK) Q1 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for McKesson (MCK) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Compared to Estimates, McKesson (MCK) Q1 Earnings: A Look at Key Metrics

McKesson Corporation (MCK) Q1 2026 Earnings Call Transcript

McKesson Corporation (NYSE:MCK ) Q1 2026 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Brian S. Tyler - CEO & Director Britt J.

McKesson Corporation (MCK) Q1 2026 Earnings Call Transcript

Zacks Investment Research

McKesson (MCK) Surpasses Q1 Earnings and Revenue Estimates

McKesson (MCK) came out with quarterly earnings of $8.26 per share, beating the Zacks Consensus Estimate of $8.23 per share. This compares to earnings of $7.88 per share a year ago.

McKesson (MCK) Surpasses Q1 Earnings and Revenue Estimates

Mckesson lifts annual profit forecast on robust demand for specialty drugs

U.S. drug distributor McKesson raised its annual profit forecast and beat Wall Street earnings estimates on Wednesday, banking on robust demand for specialty medicines.

Mckesson lifts annual profit forecast on robust demand for specialty drugs

McKesson Corporation Reports Fiscal 2026 First Quarter Results and Raises Full Year Adjusted EPS Guidance

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) has released its fiscal 2026 first quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Wednesday, August 6 at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and ar.

McKesson Corporation Reports Fiscal 2026 First Quarter Results and Raises Full Year Adjusted EPS Guidance

See News Rankings

Charts implemented using Lightweight Charts™